Clinical Trials Arena on MSN9h
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trial
Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...
Next-generation CRISPR company raises $68 million, zeroes in on first clinical trial
A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...
GEN - Genetic Engineering and Biotechnology News4h
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
The Pharma Letter7h
$68 million for Epicrispr’s development of FSHD candidate
San Francisco-based epigenetic editing company Epicrispr Biotechnologies has secured $68 million in the first close of its ...
SOLVE FSHD Announces Strategic Collaboration with Transcripta Bio to Advance Drug Discovery for FSHD
SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular ...
BioPharma Dive1d
Epicrispr banks $68M to test epigenetic editing on rare muscle disease
The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.
Precision Medicine Online4h
Epicrispr Biotechnologies Raises $68M in Series B Financing, Prepares to Launch Clinical Trial
The Series B financing will support an upcoming clinical trial in New Zealand of the company's lead program, EPI-321, in facioscapulohumeral muscular dystrophy.
Charity Today1d
Gabby Logan hosts Muscular Dystrophy UK awards
There were six awards presented, celebrating success in volunteering, fundraising, caring, community engagement and research, ...
Morningstar2d
SOLVE FSHD Announces Strategic Collaboration with Transcripta Bio to Advance Drug Discovery for FSHD
SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with ...